Narrative review of camel milk in age-related diseases and aging hallmarks
This narrative review reports that experimental and clinical findings link camel milk to oxidative stress, chronic inflammation and metabolic homeostasis across several age-related disease categories, but clinical evidence remains limited in most areas. [1]
Automatic summary · not editorially reviewed
The key findings
The review evaluates experimental and clinical findings on camel milk across metabolic, cardiovascular, neurological and immune-inflammatory age-related conditions. [1]
Reported effects involve oxidative stress, chronic inflammation and metabolic homeostasis via shared pathways, with particular engagement of chronic inflammation, deregulated nutrient sensing and dysbiosis among the hallmarks of aging. [1]
The authors state that clinical evidence remains limited in most disease areas and call for standardized trials and mechanistic validation, including bioavailability and dose-response work. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Experimental and clinical findings on camel milk in age-related diseases, as summarized in a narrative review
- Summary based on
- Study abstract
- Original publication
- September 7, 2026
Camel milk across age-related disease categories
The review evaluates experimental and clinical findings on camel milk across metabolic dysregulation, cardiovascular pathology, neurological dysfunction and immune-inflammatory conditions. It reports that camel milk has been used as a traditional health-promoting food and that growing biomedical evidence supports modulatory effects across multiple age-related conditions.
Supporting source [1]
Reported pathways and aging hallmarks
Across these conditions, the review reports modulation of oxidative stress, chronic inflammation and metabolic homeostasis through shared molecular pathways, including NF-κB, MAPK, PI3K/AKT and PPAR-α/γ signaling. Mapping these effects against the twelve hallmarks of aging shows particular engagement with chronic inflammation, deregulated nutrient sensing and dysbiosis. The authors describe this as a biologically plausible role, not a demonstrated clinical benefit.
Supporting source [1]
Limited clinical evidence and research priorities
The review states that clinical evidence remains limited across most disease areas. It calls for standardized clinical trials and systematic mechanistic validation, with particular attention to the bioavailability and dose-response characterization of key bioactive components. It presents itself as an integrative synthesis within the hallmarks of aging framework, offering a cross-disease mechanistic perspective beyond single-disease or compositional approaches.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The source is a narrative review, not a new trial, and it reports that clinical evidence is limited in most disease areas. The biologically plausible role described does not establish clinical benefit, and no dosing or safety conclusions can be drawn from the abstract.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Cheng M, Liu T, Wang X, Xue S. · europepmc.org · September 7, 2026